Combes Robert D
FRAME, Russell & Burch House, 96-98 North Sherwood Street, Nottingham NG1 4EE, UK.
Altern Lab Anim. 2004 Jun;32(2):111-7. doi: 10.1177/026119290403200208.
The involvement of the OECD in managing the validation of the rat uterotrophic assay for endocrine disruptors, and in organising the peer review of the results of this study, has been assessed and compared with the many conclusions and recommendations in several published reports of international workshops on validation, and information in guidance documents, produced by the European Centre for the Validation of Alternative Methods (ECVAM), the US Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the OECD itself. It is concluded that the OECD has not followed the recommendations for full transparency and independence of the peer-review process. This is based on the fact that it has published a draft guidance document that differs from the report of a recent OECD workshop on validation, in such a way as to give the OECD the flexibility to fully control the peer-review process and, in so doing, to avoid full transparency. Comparison of the timing of the organisation of workshops by the OECD and the progression of the validation study, together with the fact that a draft test guideline for the assay was written before completion of the peer review, suggest that the OECD has given a higher priority to the expedition of the validation and regulatory acceptance of the uterotrophic assay than it has to good scientific and logistical practice. This severely undermines its credibility in the validation process, so, in order for the OECD to be rightly perceived as an honest broker, it is recommended that the OECD should play no role in the validation of new or revised tests, until after they have been successfully validated, peer reviewed, and endorsed by the appropriate authorities, and are ready for test guideline development. With regard to the on-going OECD validation studies of other in vivo assays for endocrine disruptors, the OECD should take immediate steps to ensure full independence and transparency of their peer review.
经济合作与发展组织(OECD)在管理内分泌干扰物大鼠子宫增重试验的验证以及组织该研究结果的同行评审方面所做的工作,已根据国际验证研讨会的若干已发表报告中的诸多结论和建议,以及由欧洲替代方法验证中心(ECVAM)、美国替代方法验证跨部门协调委员会(ICCVAM)和OECD自身编制的指导文件中的信息进行了评估和比较。结论是,OECD未遵循同行评审过程全面透明和独立的建议。这是基于这样一个事实,即它发布的一份指导文件草案与OECD近期一次验证研讨会的报告不同,这种方式使OECD能够灵活地完全控制同行评审过程,并借此避免全面透明。对OECD组织研讨会的时间安排与验证研究进展情况的比较,以及该试验的测试指南草案在同行评审完成之前就已编写完成这一事实表明,OECD对子宫增重试验的验证和监管认可的推进给予了比良好的科学和后勤实践更高的优先级。这严重损害了其在验证过程中的可信度,因此,为了使OECD被正确地视为一个公正的协调者,建议在新的或修订的试验成功完成验证、同行评审并得到相关当局认可且准备好制定测试指南之前,OECD不应参与这些试验的验证工作。关于OECD正在进行的其他内分泌干扰物体内试验的验证研究,OECD应立即采取措施确保其同行评审的完全独立性和透明度。